-
Viatris received FDA approval in October 2026 to expand RYZUMVI ophthalmic solution 0.75% for treating presbyopia in adults, adding to its existing indication for pharmacologically induced mydriasis and supported by a defined safety profile from clinical trials.
-
This broader eye care use case strengthens Viatris' presence in ophthalmology, connecting a nearly universal age related condition to an already commercialized product with established prescribing guidance and usage precautions.
-
We will now examine how Viatris' investment narrative could evolve as RYZUMVI's new presbyopia indication approaches the next earnings report.
Scan how Viatris' ophthalmology pivot compares with other healthcare stocks repositioning around aging demographics by reviewing the 36 healthcare AI stocks in one focused view.
Viatris Investment Narrative Recap
To own Viatris, you need to believe the business can shift from reliance on mature generics toward higher margin areas like ophthalmology while keeping cost discipline tight. The RYZUMVI presbyopia approval fits that story, but on its own it does not change the near term reality that Viatris is still unprofitable and dealing with pricing pressure on off patent drugs.
The near term catalyst remains execution around the November 5 earnings release, where investors are watching for evidence that late stage assets and portfolio reshaping are starting to support margins. The biggest risk stays the same. Ongoing price erosion in core markets and any operational setbacks at key facilities could limit the benefit of newer launches like RYZUMVI.
The most relevant recent datapoint here is Viatris' pattern of earnings beats and a positive Earnings ESP ahead of the upcoming third quarter release. Analysts expect profit per share to decline year on year, so the focus is less on the headline number and more on how management updates the story on pipeline contribution, including ophthalmology.
If the company can show that products like RYZUMVI sit within a broader mix shift toward complex generics, biosimilars and branded therapies, that would support the existing thesis that earnings may improve over time. If guidance instead leans heavily on cost cuts while price competition remains intense, investors may treat the presbyopia approval as helpful, but not yet central to the Viatris turnaround case.
Viatris' current analyst narrative points to US$15.8b in revenue and US$704.2m in earnings by 2029, built on an assumed 2.4% yearly revenue growth rate and a swing in earnings of about US$1.1b from a loss of US$410.7m today to that 2029 consensus figure.
Uncover why Viatris' fair value indicates a 6% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
One alternate view focuses on Viatris' cost cuts rather than new products like RYZUMVI. In that story, the big swing factor is whether earnings really climb toward the bullish US$1.2b forecast by 2029 compared with about US$704m in the baseline. Both sets of analysts published before this presbyopia approval, so you may see those narratives shift.
Explore 5 other Viatris fair value estimates , including one that suggests as much as 134% upside from the current price!
The Verdict Is Yours
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
-
A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
-
See our latest analysis for Viatris. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Viatris' overall financial health at a glance.
Looking for more Viatris-sized investment ideas?
If the RYZUMVI presbyopia story has you thinking about how to position around healthcare and beyond, it can help to widen the lens and scan other opportunities using the Simply Wall St Screener.
-
For investors who want quality at a discount, you can review a curated pool of companies flagged as showing value characteristics through the 26 high quality undervalued stocks .
-
If capital preservation and steadier profiles matter most to you, focus on resilient businesses that score well on risk metrics using the 32 resilient stocks with low risk scores .
-
When you are hunting for resilient balance sheets that can absorb shocks, filter for companies with stronger financial foundations through the list of solid balance sheet and fundamentals (24 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VTRS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
